Published in Proc Natl Acad Sci U S A on August 08, 2003
MYC on the path to cancer. Cell (2012) 8.65
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med (2014) 1.51
Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. Genes Dev (2004) 1.48
c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc Natl Acad Sci U S A (2005) 1.43
c-Myc accelerates S-phase and requires WRN to avoid replication stress. PLoS One (2009) 1.32
MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer (2010) 1.18
Cdc45 is a critical effector of myc-dependent DNA replication stress. Cell Rep (2013) 1.16
DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer (2015) 1.10
Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state. Cell Rep (2013) 1.07
Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage. PLoS One (2010) 1.07
CSN6 drives carcinogenesis by positively regulating Myc stability. Nat Commun (2014) 1.06
c-Myc suppression of DNA double-strand break repair. Neoplasia (2012) 0.95
c-Myc-dependent formation of Robertsonian translocation chromosomes in mouse cells. Neoplasia (2007) 0.93
The G1 phase Cdks regulate the centrosome cycle and mediate oncogene-dependent centrosome amplification. Cell Div (2011) 0.90
c-MYC-induced genomic instability. Cold Spring Harb Perspect Med (2014) 0.89
Myc and a Cdk2 senescence switch. Nat Cell Biol (2010) 0.86
Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation. Blood (2006) 0.86
Inactivation of MYC reverses tumorigenesis. J Intern Med (2014) 0.84
MYC is a critical target of FBXW7. Oncotarget (2015) 0.83
Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening. BMC Cancer (2014) 0.82
Histone H2AX suppresses translocations in lymphomas of Eμ-c-Myc transgenic mice that contain a germline amplicon of tumor-promoting genes. Cell Cycle (2013) 0.81
The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. Leukemia (2013) 0.81
Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia. Cancers (Basel) (2013) 0.80
Multi-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients. Cell Cycle (2014) 0.80
A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. Mol Cancer (2008) 0.79
Cdc6 cooperates with c-Myc to promote genome instability and epithelial to mesenchymal transition EMT in zebrafish. Oncotarget (2014) 0.79
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol (2016) 0.78
c-MYC-Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease. Genes (Basel) (2017) 0.75
Essential roles of Caspase-3 in facilitating Myc-induced genetic instability and carcinogenesis. Elife (2017) 0.75
The Dual Roles of MYC in Genomic Instability and Cancer Chemoresistance. Genes (Basel) (2017) 0.75
The DNA damage response: putting checkpoints in perspective. Nature (2000) 19.07
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol (1999) 16.81
A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet (1997) 12.94
DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet (2001) 10.77
Proliferation, cell cycle and apoptosis in cancer. Nature (2001) 9.57
XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev (1999) 9.50
The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol (2000) 8.47
Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell (1999) 8.03
c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell (2002) 5.47
Suppression of spontaneous chromosomal rearrangements by S phase checkpoint functions in Saccharomyces cerevisiae. Cell (2001) 4.96
Multiple pathways cooperate in the suppression of genome instability in Saccharomyces cerevisiae. Nature (2001) 3.77
The myc oncogene: MarvelouslY Complex. Adv Cancer Res (2002) 3.68
Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A (2002) 3.55
Frequent chromosomal translocations induced by DNA double-strand breaks. Nature (2000) 3.27
Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A (1999) 3.24
Coupled homologous and nonhomologous repair of a double-strand break preserves genomic integrity in mammalian cells. Mol Cell Biol (2000) 2.57
Double-strand breaks and tumorigenesis. Trends Cell Biol (2001) 2.53
Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci U S A (1995) 2.43
ATP hydrolysis by mammalian RAD51 has a key role during homology-directed DNA repair. J Biol Chem (2002) 1.97
Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood (2002) 1.84
Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci U S A (2000) 1.70
Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. Cancer Res (1998) 1.48
c-Myc overexpression uncouples DNA replication from mitosis. Mol Cell Biol (1999) 1.42
Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1. Oncogene (1995) 1.41
Spontaneous DNA damage, genome instability, and cancer--when DNA replication escapes control. Cell (2001) 1.28
Hus1 acts upstream of chk1 in a mammalian DNA damage response pathway. Curr Biol (2002) 1.19
c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene (1996) 1.19
Myc-Is this the oncogene from Hell? Cancer Cell (2002) 1.10
Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA-damaging agents. Oncogene (1998) 1.04
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer (2010) 3.64
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol (2014) 3.07
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med (2009) 2.31
An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med (2008) 2.12
Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol (2004) 2.05
Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature (2011) 2.03
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc Natl Acad Sci U S A (2006) 1.89
Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Res (2005) 1.85
Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood (2002) 1.84
Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol (2006) 1.82
The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev (2010) 1.81
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest (2015) 1.67
The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A (2004) 1.63
Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res (2008) 1.58
MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res (2006) 1.57
Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med (2011) 1.56
Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One (2008) 1.46
Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed Engl (2009) 1.44
Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer (2011) 1.37
MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res (2011) 1.32
Development of a micro-computed tomography-based image-guided conformal radiotherapy system for small animals. Int J Radiat Oncol Biol Phys (2010) 1.29
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One (2013) 1.28
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood (2007) 1.27
Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci U S A (2009) 1.25
Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. PLoS Genet (2008) 1.23
CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med (2013) 1.22
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res (2011) 1.20
Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proc Natl Acad Sci U S A (2007) 1.19
Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clin Cancer Res (2006) 1.18
Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol (2004) 1.17
Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS Genet (2012) 1.15
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci U S A (2011) 1.13
SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One (2012) 1.13
Conditionally MYC: insights from novel transgenic models. Cancer Lett (2004) 1.10
Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. J Biol Chem (2005) 1.10
Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. J Clin Invest (2011) 1.10
Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther (2009) 1.09
The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse. Am J Pathol (2009) 1.08
Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res (2005) 1.07
Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure. PLoS One (2009) 1.04
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet (2012) 1.04
Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biol Ther (2007) 1.00
HIF-2α suppresses p53 to enhance the stemness and regenerative potential of human embryonic stem cells. Stem Cells (2012) 0.99
Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. PLoS One (2008) 0.99
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol (2010) 0.98
CDK2 is required by MYC to induce apoptosis. Cell Cycle (2006) 0.96
Activating HRAS mutation in agminated Spitz nevi arising in a nevus spilus. JAMA Dermatol (2013) 0.96
Genomic DNA microarray analysis: identification of new genes regulated by light color in the cyanobacterium Fremyella diplosiphon. J Bacteriol (2004) 0.95
"Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget (2012) 0.95
Rho isoform-specific interaction with IQGAP1 promotes breast cancer cell proliferation and migration. J Biol Chem (2012) 0.94
Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Res (2010) 0.93
Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model. Oncogene (2005) 0.93
MYC can enforce cell cycle transit from G1 to S and G2 to S, but not mitotic cellular division, independent of p27-mediated inihibition of cyclin E/CDK2. Cell Cycle (2006) 0.93
Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res (2013) 0.92
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood (2013) 0.92
Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol (2015) 0.91
How cancers escape their oncogene habit. Cell Cycle (2003) 0.90
A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements. Clin Lung Cancer (2013) 0.90
Rehabilitation of cancer through oncogene inactivation. Trends Mol Med (2005) 0.89
Getting at MYC through RAS. Clin Cancer Res (2005) 0.89
High throughput automated chromatin immunoprecipitation as a platform for drug screening and antibody validation. Lab Chip (2012) 0.88
Metabolic changes in cancer cells upon suppression of MYC. Cancer Metab (2013) 0.88
Noninvasive molecular imaging of c-Myc activation in living mice. Proc Natl Acad Sci U S A (2010) 0.86
Myc and a Cdk2 senescence switch. Nat Cell Biol (2010) 0.86
Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology (2009) 0.86
Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. Adv Exp Med Biol (2013) 0.86
(18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. Cancer Biol Ther (2008) 0.85
Effects of long-term culture on human embryonic stem cell aging. Stem Cells Dev (2010) 0.85
Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. PLoS One (2010) 0.84
Characterization of MYC-induced tumorigenesis by in situ lipid profiling. Anal Chem (2013) 0.83
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opin Investig Drugs (2013) 0.83
Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. Blood (2010) 0.83
An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunol Res (2014) 0.83
Noncanonical roles of the immune system in eliciting oncogene addiction. Curr Opin Immunol (2013) 0.80
Oncogenes as therapeutic targets. Semin Cancer Biol (2004) 0.79
Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution. Am J Surg Pathol (2013) 0.79
Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. PLoS One (2011) 0.79
Early lung cancer detection based on registered perfusion MRI. Oncol Rep (2006) 0.79
A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. Mol Cancer (2008) 0.79
Role of MYCN in retinoblastoma. Lancet Oncol (2013) 0.79
A bipartite graph matching framework for finding correspondences between structural elements in two proteins. Conf Proc IEEE Eng Med Biol Soc (2004) 0.79
Sequencing of a QTL-rich region of the Theobroma cacao genome using pooled BACs and the identification of trait specific candidate genes. BMC Genomics (2011) 0.78
Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. J Biol Chem (2011) 0.77
Identifying critical signaling molecules for the treatment of cancer. Recent Results Cancer Res (2007) 0.77
Rapid detection of Escherichia coli O157:H7 spiked into food matrices. Anal Chim Acta (2006) 0.77
A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. Mol Cancer Ther (2013) 0.76